SYBR-Green I fluorescence-based qRT-PCR of clove oil's anticancer, chemical characterization and antidiabetic activities

Omar Yassen, Ali and Arif Muhammed, Rozhan and Uthirapathy, Subasini (2023) SYBR-Green I fluorescence-based qRT-PCR of clove oil's anticancer, chemical characterization and antidiabetic activities. Journal of Population Therapeutics and Clinical Pharmacology, 30 (11). pp. 125-134.

Text (Research Article) 125-134_LEAD115943.pdf - Published Version Download (639kB)

Abstract

Syzygium aromaticum is a valuable herbal plant in China, Europe, and Asia. It has been described as a powerful analgesic, anti-inflammatory, antioxidant, antifungal, and antibacterial agent. The goal of this work is to determine the phytoconstituents in clove oil derived from Syzygium aromaticum, a Myrtaceae family member. The GC-MS analysis of clove essential oil revealed 23 chemical compounds, including eugenol (58.65%), caryophyllene (6.60%), camphane (monoterpenes) (2.95%), Bisabolol (7.31%), tricosane (3.80%), eugenol acetate (3.35%), naphthalene (18.81%), and endo-borneol (19.98%). Certain organic acids such as benzoic acid (33.65%), acetic acid (9.30%), cinnamic acid (6.69%), and phenol (5.47 %). The anti-diabetic activity was evaluated utilizing an α-amylase suppression analysis. The anticancer effect of Cas 3 gene expression analysis by qRT-PCR was assessed in a human bone cancer cell line (MG-63). Clove oil inhibited the α -amylase enzyme concentration-dependently, with an IC50 value (IC50 167.24.46 μg/ml) equivalent to that of conventional acarbose (IC50 85.393.14 μg/ml). The results of real-time qRT-PCR revealed that following treatment with clove oil with an IC50 value of 33.6 μg/ml, the Cas 3 gene expression level in -actin and the human bone cancer cell line (MG-63) was expressed with a fold gene variation difference of 2.07. According to one study, clove oil could be utilized to treat diabetes and human bone cancer.

Actions (login required)

View Item